Recombinant Human CLEC1B, N-His

Description of Recombinant Human CLEC1B, N-His

Introduction

Recombinant Human CLEC1B, also known as C-type lectin domain family 1 member B, is a protein that plays a vital role in the immune system. This protein belongs to the C-type lectin family, which is known for their ability to bind to carbohydrates and play a role in various biological processes. Recombinant Human CLEC1B is a genetically engineered version of the naturally occurring protein, produced in a laboratory setting for various scientific and medical applications.

Structure of Recombinant Human CLEC1B

Recombinant Human CLEC1B is a glycoprotein, meaning it contains sugar molecules attached to its amino acid chains. It is composed of 214 amino acids and has a molecular weight of approximately 24 kDa. The protein has a single C-type lectin domain, which is responsible for its carbohydrate binding activity. This domain is made up of a beta-sandwich structure with two calcium ions, which are crucial for its stability and function.

Activity of Recombinant Human CLEC1B

Recombinant Human CLEC1B is primarily expressed on the surface of immune cells, such as dendritic cells, monocytes, and macrophages. It functions as a pattern recognition receptor, recognizing and binding to specific carbohydrate structures on the surface of pathogens. This binding triggers a signaling cascade that activates the immune response, leading to the elimination of the pathogen.

In addition to its role in the immune system, Recombinant Human CLEC1B has also been found to play a role in angiogenesis, the formation of new blood vessels. It binds to a specific protein called podoplanin, which is expressed on the surface of endothelial cells, promoting their migration and proliferation. This activity of Recombinant Human CLEC1B makes it a potential target for anti-cancer therapies, as angiogenesis is crucial for tumor growth and metastasis.

Applications of Recombinant Human CLEC1B

Recombinant Human CLEC1B has various applications in the field of research and medicine. Its ability to bind to specific carbohydrates makes it a valuable tool for studying carbohydrate-protein interactions. It has been used in structural studies to understand the mechanism of carbohydrate recognition by C-type lectins.

In the medical field, Recombinant Human CLEC1B has shown potential as a diagnostic and therapeutic agent. Its role in the immune system makes it a potential biomarker for certain diseases, such as autoimmune disorders and viral infections. It can also be used as a therapeutic target for the development of new drugs to treat these diseases.

Furthermore, Recombinant Human CLEC1B has been studied for its potential in cancer treatment. Its ability to inhibit angiogenesis and promote immune response makes it a promising candidate for anti-cancer therapies. It has been shown to inhibit tumor growth and metastasis in pre-clinical studies, and further research is being conducted to explore its potential as a cancer treatment.

Conclusion

In summary, Recombinant Human CLEC1B is a glycoprotein that plays a crucial role in the immune system and angiogenesis. Its structure, activity, and potential applications make it a valuable protein in the field of research and medicine. Further studies and developments in this area can lead to the use of Recombinant Human CLEC1B in various diagnostic and therapeutic applications, ultimately benefiting human health.